The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2018 | Allogeneic therapy for the treatment of refractory hematological malignancies
There has been an increase in the number of patients with refractory hematological malignancies being referred to transplant centers, although previously, treatment was limited for refractory conditions. In this talk, Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France, alludes to the optimism regarding allogeneic therapy for patients with refractory hematological malignancies. Talking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Prof. Mohty discusses the potential candidates for allogeneic transplantation.
